Antileukemic Effects of Deferoxamine on Human Myeloid Leukemia Cell Lines

Cancer Research

Volumn 49, Issue 17, 1989, Pages 4809-4812

  Becton, David L ^a   Roberts, Barbara ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; RADIOISOTOPE;

ANTINEOPLASTIC ACTIVITY; CELL CULTURE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MYELOID LEUKEMIA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL DIVISION; DEFEROXAMINE; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMAN; LEUKEMIA, MYELOID; METHYLCELLULOSE; NEOPLASM PROTEINS; RNA, NEOPLASM; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0024343393     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Lederman, H. M., Cohen, A., Lee, J. W. W., Freedman, M. H., and Gelfland, E. W. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood, 64:748–753, 1984.
2. Bowern, N., Ramshaw, P., Badenocch-Jones, P., and Doherty, P. C. Effect of an iron-chelating agent on lymphocyte proliferation. Aust. J. Exp. Biol. Med. Sci., 62:743–754, 1984.
3. Matzner, Y., Hershko, C., Polliack, A., Konjin, A. M., and Izak, G. Suppressive effect of ferritin on in vitro lymphocyte function. Br. J. Haematol., 42:345–353, 1979.
4. Hoffbrand, A. V., Ganeshaguru, K., Hooton, J. W. C., and Tattersall, M. H. N. Effect of iron deficiency and desferrioxamine DNA synthesis in human cells. Br. J. Haematol., 33:517–526.
5. Bomford, A., Isaac, J., Roberts, S., Edwards, A., Young, S., and Williams, R. The effect of desferrioxamine on transferrin receptors, the cell cycle and growth rates of human leukaemic cells. Biochem. J., 236:243–249, 1986.
6. Forsbeck, L., Bjelkenkrantz, K., and Nilsson, K. Role of iron in the proliferation of the established human tumor cell lines U-937 and K-562: effects of suramin and a lipophilic iron chelator (PIH). Scand. J. Haematol., 37: 429–437, 1986.
7. Blatt, J., and Stitely, S. Antineuroblastoma activity of desferoxamine in human cell lines. Cancer Res., 47:1749–1750, 1987.
8. Becton, D. L., and Bryles, P. Deferoxamine affects viability and clonal growth of human leukemia cells. Clin. Res., 36:68A, 1988.
9. Becton, D. L., and Bryles, P. Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res., 48:7189–7192, 1988.
10. Estrov, B., Tawa, A., Wang, X. O. H., Dube, I., Sulh, H., Cohen, A., Gelfand, E., and Freedman, M. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood, 69:757–761, 1987.
11. Hann, H. L., Stahlhut, M. W., and London, W. T. Anti-tumor activity of an iron chelating agent (desferoxamine) on human hepatoma cell lines. Clin. Res., 36:495A, 1988.
12. Modell, B., Letsky, E., Flynn, D., Reto, R., and Weatherall, D. Survival and desferoxamine in thalassemia major. Br. Med. J., 284:1081–1084, 1982.
13. Allain, P., Mauras, Y., Chaleil, D., Simon, P., Ang, K., Cam, G., LeMignon, L., and Simon, M. Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. Br. J. Clin. Pharmacol., 24:207–212, 1987.
14. Wolf, L., Leitzel, K., Witkoski, E., Bartholomew, M., and Lipton, A. Desferrioxamine prolongs survival of mice with LI210 lymphocytic leukemia. Proc. Am. Assoc. Cancer Res., 29:2053, 1988.